Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Glaukos

NYSE: GKOS ↗$164.01 USD~$9.1B MCAP

Ophthalmic pharmaceutical and medical device company developing therapies and surgical devices for glaucoma and corneal disorders.

Company Info

Sector:Medical Devices
Headquarters:Aliso Viejo, California, USA
Founded:1998

Clinical Development Pipeline

iDose TR

Target: Trabecular meshwork (prostaglandin analog delivery)
Open-angle glaucoma / ocular hypertension
Preclinical
Phase 1
Phase 2
Phase 3
Approved

iStent infinite

Target: Trabecular micro-bypass
Glaucoma uncontrolled by prior medical and surgical therapy
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Epioxa

Target: Corneal cross-linking
Keratoconus
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Thomas W. Burns

President and Chief Executive Officer

Careers & Job Openings

See all open roles

Various
Aliso Viejo, CA / Remote
Apply Now →